Editas Medicine, Inc.
EDIT
$2.35
-$0.11-4.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -19.16% | 12,265.57% | 597.47% | 310.40% | -49.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.16% | 12,265.57% | 597.47% | 310.40% | -49.03% |
| Cost of Revenue | -43.63% | -58.49% | -70.15% | -45.49% | -30.11% |
| Gross Profit | 85.21% | 74.29% | 76.53% | 53.97% | -89.41% |
| SG&A Expenses | -30.58% | -31.91% | -29.37% | -30.84% | 13.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.34% | -51.18% | -59.90% | -41.33% | -22.67% |
| Operating Income | 59.21% | 62.62% | 64.59% | 47.29% | -43.40% |
| Income Before Tax | 87.62% | 59.58% | 21.26% | -22.82% | -140.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 87.62% | 59.58% | 21.26% | -22.82% | -140.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.62% | 59.58% | 21.26% | -22.82% | -140.52% |
| EBIT | 59.21% | 62.62% | 64.59% | 47.29% | -43.40% |
| EBITDA | 57.64% | 62.81% | 66.48% | 49.08% | -38.65% |
| EPS Basic | 89.48% | 62.99% | 23.22% | -21.16% | -137.88% |
| Normalized Basic EPS | 75.17% | 63.00% | 60.85% | 43.89% | -89.93% |
| EPS Diluted | 89.48% | 62.99% | 23.22% | -21.16% | -137.88% |
| Normalized Diluted EPS | 75.17% | 63.00% | 60.85% | 43.89% | -89.93% |
| Average Basic Shares Outstanding | 17.72% | 9.22% | 2.55% | 1.36% | 1.11% |
| Average Diluted Shares Outstanding | 17.72% | 9.22% | 2.55% | 1.36% | 1.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |